Economic impact of primary open-angle glaucoma in Australia
- PMID: 21631669
- DOI: 10.1111/j.1442-9071.2011.02530.x
Economic impact of primary open-angle glaucoma in Australia
Abstract
Background: Glaucoma is the World's leading cause of irreversible blindness, and poses serious public health and economic concerns.
Design: Review.
Samples: Published randomized trials and population-based studies since 1985.
Methods: We report the economic impact of primary open-angle glaucoma and model the effect of changes in detection rates and management strategies.
Main outcome measures: The cost-effectiveness of different interventions to prevent vision loss from primary open-angle glaucoma was measured in terms of financial cost (Australian dollars) and disability-adjusted life years.
Results: The prevalence of glaucoma in Australia is expected to increase from 208 000 in 2005 to 379 000 in 2025 because of the aging population. Health system costs over the same time period are estimated to increase from $AU355 million to $AU784 million. Total costs (health system costs, indirect costs and costs of loss of well-being) will increase from $AU1.9 billion to $AU4.3 billion in Australia.
Conclusion: Primary open-angle glaucoma poses a significant economic burden, which will increase substantially by 2025. This dynamic model provides a valuable tool for ongoing policy formulation and determining the economic impact of interventions to better prevent visual impairment and blindness from glaucoma.
© 2011 The Authors. Clinical and Experimental Ophthalmology © 2011 Royal Australian and New Zealand College of Ophthalmologists.
Similar articles
-
Comparing the effectiveness of selective laser trabeculoplasty with topical medication as initial treatment (the Glaucoma Initial Treatment Study): study protocol for a randomised controlled trial.Trials. 2015 Sep 11;16:406. doi: 10.1186/s13063-015-0924-6. Trials. 2015. PMID: 26362541 Free PMC article. Clinical Trial.
-
Economic considerations of the diagnosis and management for glaucoma in the developed world.Curr Opin Ophthalmol. 2011 Mar;22(2):102-9. doi: 10.1097/ICU.0b013e3283437bf0. Curr Opin Ophthalmol. 2011. PMID: 21192264 Review.
-
Glaucoma: where to now?Ophthalmology. 2009 May;116(5):821-2. doi: 10.1016/j.ophtha.2009.01.042. Ophthalmology. 2009. PMID: 19410940 No abstract available.
-
The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.Ophthalmology. 2009 May;116(5):823-32. doi: 10.1016/j.ophtha.2008.12.056. Epub 2009 Mar 14. Ophthalmology. 2009. PMID: 19285730
-
The glaucomas.Minerva Med. 2001 Oct;92(5):365-79. Minerva Med. 2001. PMID: 11675580 Review.
Cited by
-
Relation between a history of glaucoma and subjective happiness: the JPHC-Next study.BMJ Open Ophthalmol. 2024 Feb 19;9(1):e001553. doi: 10.1136/bmjophth-2023-001553. BMJ Open Ophthalmol. 2024. PMID: 38373803 Free PMC article.
-
Comparative Analysis of Surgical Durations and Fees Across Eight Types of Glaucoma Surgery Performed by a Single Surgeon.Cureus. 2024 Jan 4;16(1):e51675. doi: 10.7759/cureus.51675. eCollection 2024 Jan. Cureus. 2024. PMID: 38313883 Free PMC article.
-
Price tag of glaucoma care is minor compared with the total direct and indirect costs of glaucoma: Results from nationwide survey and register data.PLoS One. 2023 Dec 20;18(12):e0295523. doi: 10.1371/journal.pone.0295523. eCollection 2023. PLoS One. 2023. PMID: 38117760 Free PMC article.
-
Cost-utility analysis of commonly used anti-glaucoma interventions for mild-to-moderate primary open-angle glaucoma patients in rural and urban China.BMJ Open. 2023 Sep 6;13(9):e073219. doi: 10.1136/bmjopen-2023-073219. BMJ Open. 2023. PMID: 37673456 Free PMC article.
-
Oxidative Stress: A Suitable Therapeutic Target for Optic Nerve Diseases?Antioxidants (Basel). 2023 Jul 20;12(7):1465. doi: 10.3390/antiox12071465. Antioxidants (Basel). 2023. PMID: 37508003 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
